Health News Releases

  • Today March 12
08:36
Chiesi and Bespak Partner to Advance Carbon Minimal Inhaler Production With UK Manufacturing Site
Chiesi Group (“Chiesi”), the international research focused biopharmaceutical company and a certified B Corp, and Bespak, the specialist inhalation CDMO focused on pulmonary and nasal drug delivery, t
March 11, 15:53
Galderma Buys Back Shares Worth CHF 232 Million in the Context of Accelerated Bookbuild Offering
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it has agreed to repurchase 1.6 million shares at a price of CHF 143.75 per share for a total consideration of CHF
March 11, 15:52
Galderma Completes Successful Placement of EUR 500 Million Eurobond
Galderma Group AG (SWX:GALD): NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR REGULATION. Galderma Grou
WHOOP Broadens WHOOP Advanced Labs Offering, Announcing a Women’s Health Specialized Blood Biomarker
March 11, 15:45
WHOOP Broadens WHOOP Advanced Labs Offering, Announcing a Women’s Health Specialized Blood Biomarker Panel
WHOOP (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.whoop.com%2Fus%2Fen%2F&esheet=54439889&newsitemid=20260310966566&lan=en-US&anchor=WHOOP&index=1&md5=45c5be6cf83ed6f2f43c9ea
March 11, 08:44
For the First Time, Ferring Reports Revenue of Over €2.5 Billion in 2025
Ferring today published its 2025 Annual Report (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.ferring.com%2Fwp-content%2Fuploads%2Fsites%2F16%2F2026%2F03%2FFerring-Pharmaceutic
March 10, 09:43
Galderma Introduces Cetaphil AM/PM Antioxidant Serums, a New Science-Driven Defense and Recovery System for Sensitive Skin
Galderma (SIX: GALD) today announced Cetaphil, the dermatologist-recommended brand trusted by millions with sensitive skin, is launching its new Cetaphil AM/PM Antioxidant Serums, a breakthrough daily
Medical Korea 2026 will take place at Coex, Seoul, from March 19 (Thu) to 22 (Sun), themed on ‘AI-Po
March 06, 16:22
Medical Korea 2026 Spotlights AI-Powered Global Healthcare Transformation and Cross-Border Medical Services
Medical Korea 2026 (https://www.mkconf.org/fairDash.do?hl=ENG), the 16th Global Healthcare & Medical Tourism Conference, will take place March 19-22, 2026, at COEX in Seoul. Hosted by the Ministry
March 05, 16:04
Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency, and Core EBITDA of 1.211 billion USD, Growing 18.9% at Constant Currency
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. · Record net sales of 5,207 million USD, surpassing 5 billion
WHOOP Announces 2026 Hiring Surge, Adding More Than 600 Roles as It Scales Wearable Health Platform
March 05, 15:40
WHOOP Announces 2026 Hiring Surge, Adding More Than 600 Roles as It Scales Wearable Health Platform Globally
WHOOP (https://www.whoop.com/kr/en/), the human performance company, today announced plans to add more than 600 new roles across Software, Research & Design, Hardware, Product, and Marketing as the co
March 05, 09:20
Linnea Achieves CEP Certification for Cannabidiol Isolate
Linnea is proud to announce that its Cannabidiol (CBD) Isolate has been granted a Certificate of Suitability to the European Pharmacopoeia (CEP). The CEP serves to attest that the quality of an act
Swiss Advanced Vision premium IOL lenses for cataract surgery
March 04, 15:50
Lucidis® Sets High Standards in Premium Cataract Surgery with Full-Range Vision Performance
Swiss Advanced Vision announces new clinical evidence confirming the exceptional performance of its Lucidis® intraocular lens (IOL), strengthening its position as a disruptive solution in premium cata
March 04, 11:11
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=54436160&newsitemid=20260301580219&lan=en-US&anchor=TSE%3A4502%2FNYSE%
Controller and processor, Filter-less culture bag and reservoir/waste bags *Controller and other acc
March 03, 15:45
PHCbi Launches LiCellGrow™ Cell Expansion System to Support High-Quality and Efficient Production of Cell and Gene Therapies
PHC Corporation’s Biomedical Division (Head Office: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura; hereinafter “PHCbi”), a global provider of laboratory sample storage and cell cultivation solutions
March 03, 14:20
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE034
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innova
Cowellnex and Metagen Launch Joint Research Utilizing Independently Acquired High‑Precision Gut Microbiota Data
March 02, 13:30
Cowellnex and Metagen Launch Joint Research Utilizing Independently Acquired High‑Precision Gut Microbiota Data
Cowellnex Co., Ltd. (Cowellnex)—jointly established by Kirin Holdings Company, Limited (Kirin Holdings)(TOKYO:2503) and Kyowa Kirin Co., Ltd. (Kyowa Kirin)—and Metagen, Inc. (Metagen), which promotes
March 02, 11:55
BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership
BeOne Medicines Ltd. (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fbeonemedicines.com%2F&esheet=54433496&newsitemid=20260226660598&lan=en-US&anchor=BeOne+Medicines+Ltd.&index=1&md
February 27, 15:39
Galderma’s Nemluvio® (nemolizumab) Demonstrates Long-Term Disease Control in Prurigo Nodularis up to Three Years
Galderma (SIX: GALD) today announced new data from the OLYMPIA open-label extension study investigating the long-term safety and efficacy of Nemluvio in moderate-to-severe prurigo nodularis.1 Results
February 27, 14:30
Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics
Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces the signing of a term sheet for a strategic asset acqui
February 25, 15:58
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics
Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-art syringe for use with its NASHA® lidocaine range of Restylane prod
Angelini Pharma and Quiver Bioscience Announce Strategic Research Collaboration and Licensing Agreement to Discover and Advance Novel Therapeutics for Genetic Epilepsies
February 24, 16:26
Angelini Pharma and Quiver Bioscience Announce Strategic Research Collaboration and Licensing Agreement to Discover and Advance Novel Therapeutics for Genetic Epilepsies
Angelini Pharma (https://www.angelinipharma.com/), part of the privately owned Angelini Industries, and Quiver Bioscience (https://www.quiverbioscience.com/) (“Quiver”), a discovery technology and the
February 24, 16:10
Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has entered into an agreement to exclusi
Rare Diseases: Collaboration is key. image: AdobeStock_1308212316
February 24, 10:15
AOP Health on Rare Diseases: Information. Collaboration. Innovation.
Between 27 and 36 million[1] people in Europe are living with a rare disease, yet only around six percent currently have access to an approved treatment[2]. Progress in diagnosis and treatment is ofte
February 22, 09:40
YolTech Therapeutics Announces Positive Interim Data on YOLT-202 for the Treatment of Alpha-1 Antitrypsin Deficiency
YolTech Therapeutics (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.yoltx.com%2F&esheet=54428688&newsitemid=20260219197004&lan=en-US&anchor=YolTech+Therapeutics&index=1&md5=5e9
February 20, 09:57
Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis
Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54427813&newsitemid=20260218745615&lan=en-US&anchor=TSE%3A4
Michael Clay, Caidya's Chief Operating Officer
February 18, 13:05
Caidya Names Michael Clay COO to Drive Operational Excellence and Advance Multi-Regional Clinical Development
Caidya (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.caidya.com%2F&esheet=54426559&newsitemid=20260217431202&lan=en-US&anchor=Caidya&index=1&md5=7b2712d1d79f058b73bc0260a86357
25 per page50 per page75 per page100 per page